Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Saghmos Therapeutics, Inc.
Saghmos Therapeutics Announces Collaboration with Duke Clinical Research Institute to Optimize Phase 3 Cardio-Renal Metabolic Study
April 17, 2024
From
Saghmos Therapeutics, Inc.
Via
Business Wire
Saghmos Therapeutics Announces Receipt of Notice of Allowance from Japanese Patent Office for Phase 3-Ready Cardiorenal Metabolic Modulator ST-62516
March 12, 2024
From
Saghmos Therapeutics, Inc.
Via
Business Wire
Saghmos Therapeutics Announces Appointment of FDA Veteran Stephen Grant, MD, as Chief Regulatory Officer
February 21, 2024
From
Saghmos Therapeutics, Inc.
Via
Business Wire
Saghmos Therapeutics Announces Notice of Allowance for Second US Patent for Phase 3-Ready Cardiorenal Metabolic Modulator ST-62516
February 07, 2024
From
Saghmos Therapeutics, Inc.
Via
Business Wire
Saghmos Therapeutics Announces Appointment of Pharmaceutical Industry Veteran Fred Hassan as Chairman of the Board of Directors
October 03, 2023
From
Saghmos Therapeutics, Inc.
Via
Business Wire
Saghmos Therapeutics Announces Issuance of US Patent for ST-62516 for the Reduction of Kidney Injury in Patients with Chronic Kidney Disease Undergoing Contrast Procedures
November 17, 2021
From
Saghmos Therapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.